Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 14/20 | 0.79 |
| ▸ | FGFR1 | P11362 | 9/20 | 0.79 |
| ▸ | FGFR2 | P21802 | 5/20 | 0.79 |
| ▸ | FGFR4 | P22455 | 5/20 | 0.79 |
| ▸ | LCK | P06239 | 4/20 | 0.79 |
| ▸ | JAK2 | O60674 | 2/20 | 0.79 |
| ▸ | ABL1 | P00519 | 2/20 | 0.79 |
| ▸ | INSR | P06213 | 2/20 | 0.79 |
| ▸ | FYN | P06241 | 2/20 | 0.79 |
| ▸ | YES1 | P07947 | 2/20 | 0.79 |
| ▸ | LYN | P07948 | 2/20 | 0.79 |
| ▸ | RET | P07949 | 2/20 | 0.79 |
| ▸ | MET | P08581 | 2/20 | 0.79 |
| ▸ | ROS1 | P08922 | 2/20 | 0.79 |
| ▸ | KIT | P10721 | 2/20 | 0.79 |
| ▸ | SRC | P12931 | 2/20 | 0.79 |
| ▸ | BRAF | P15056 | 2/20 | 0.79 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.79 |
| ▸ | FLT1 | P17948 | 2/20 | 0.79 |
| ▸ | TYK2 | P29597 | 2/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL583166 | 0.91 | FGFR3 (0.86) | FGFR3FGFR1FGFR2FGFR4LCK | |
| Infigratinib SCHEMBL374435 | 0.89 | FGFR3 (1.00) | FGFR3FGFR1FGFR2FGFR4LCK | |
| SCHEMBL374149 | 0.89 | FGFR3 (0.80) | FGFR3FGFR1FGFR2FGFR4LCK | |
| SCHEMBL22532275 | 0.88 | FGFR3 (0.62) | FGFR3FGFR1FGFR2FGFR4LCK | |
| SCHEMBL19250256 | 0.87 | FGFR1 (0.84) | FGFR3FGFR1FGFR2FGFR4CYP3A4 | |
| SCHEMBL27168259 | 0.87 | FGFR3 (0.61) | FGFR3FGFR1FGFR2FGFR4LCK | |
| SCHEMBL22532488 | 0.87 | FGFR3 (0.85) | FGFR3FGFR1FGFR2FGFR4LCK | |
| SCHEMBL29291599 | 0.86 | FGFR3 (0.81) | FGFR3FGFR1FGFR2FGFR4LCK | |
| SCHEMBL24490250 | 0.86 | FGFR3 (0.75) | FGFR3FGFR1FGFR2FGFR4LCK | |
| SCHEMBL22532567 | 0.86 | FGFR3 (0.83) | FGFR3FGFR1FGFR2FGFR4LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1976847-B1 | PYRIMIDINYL ARYL UREA DERIVATIVES BEING FGF INHIBITORS | NOVARTIS AG (CH) | 2015-06-17 | — | — | EP | claimed |
| EP-2512476-A1 | METHOD FOR TREATING HAEMATOLOGICAL CANCERS | Novartis AG (CH) | 2012-10-24 | — | — | EP | claimed |
| US-8293746-B2 | Pyrimidinyl aryl urea derivatives being FGF inhibitors | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | claimed |
| US-20120258940-A1 | METHOD FOR TREATING HAEMATOLOGICAL CANCERS | NOVARTIS AG (CH) | 2012-10-11 | — | — | US | claimed |
| WO-2011075620-A1 | METHOD FOR TREATING HAEMATOLOGICAL CANCERS | NOVARTIS AG (CH) | 2011-06-23 | — | — | WO | claimed |
| US-20080312248-A1 | Pyrimidinyl Aryl Urea Derivatives Being Fgf Inhibitors | NOVARTIS AG | 2008-12-18 | — | — | US | claimed |
| EP-1976847-A2 | PYRIMIDINYL ARYL UREA DERIVATIVES BEING FGF INHIBITORS | Novartis AG (CH) | 2008-10-08 | — | — | EP | claimed |
| WO-2007071752-A2 | PYRIMIDINYL ARYL UREA DERIVATIVES BEING FGF INHIBITORS | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | claimed |
| CN-117916231-A | Compounds for inhibiting or degrading target proteins, compositions comprising the same, methods of making and methods of using the same | 纽力克斯治疗公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-114933589-B | Compound for inducing FGFR degradation based on CRBN ligand and preparation method and application thereof | 杭州医学院 | 2024-03-26 | — | — | CN | disclosed |
| EP-4334302-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | Nurix Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| CN-114940674-B | Compound for inducing FGFR3-TACC3 degradation based on CRBN ligand and preparation method and application thereof | 杭州医学院 | 2023-12-22 | — | — | CN | disclosed |
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20130030171-A1 | Pyrimidinyl Aryl Urea Derivatives being FGF Inhibitors | NOVARTIS AG (CH) | 2013-01-31 | — | — | US | disclosed |
| EP-2512476-A1 | METHOD FOR TREATING HAEMATOLOGICAL CANCERS | Novartis AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| US-8293746-B2 | Pyrimidinyl aryl urea derivatives being FGF inhibitors | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20120258940-A1 | METHOD FOR TREATING HAEMATOLOGICAL CANCERS | NOVARTIS AG (CH) | 2012-10-11 | — | — | US | disclosed |
| WO-2011075620-A1 | METHOD FOR TREATING HAEMATOLOGICAL CANCERS | NOVARTIS AG (CH) | 2011-06-23 | — | — | WO | disclosed |
| US-20080312248-A1 | Pyrimidinyl Aryl Urea Derivatives Being Fgf Inhibitors | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258940-A1 | METHOD FOR TREATING HAEMATOLOGICAL CANCERS | FGFR3, FGFR2, FGFR1 | FGFR3 1/4885FGFR1 3/4885FGFR2 2/4885 |
| US-20080312248-A1 | Pyrimidinyl Aryl Urea Derivatives Being Fgf Inhibitors | FGFR1, FGF1, FGF2 | FGFR3 5/4885FGFR1 1/4885FGFR2 4/4885 |
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | MDM2, XIAP, ADRM1 | FGFR3 3719/4885FGFR1 3985/4885FGFR2 3869/4885 |
| US-20130030171-A1 | Pyrimidinyl Aryl Urea Derivatives being FGF Inhibitors | FGFR1, FGF1, FGF2 | FGFR3 5/4885FGFR1 1/4885FGFR2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.